Valentina K. Todorova*, Issam Makhoul†, Ishwori Dhakal‡, Jeanne Wei§, Annjanette Stone¶, Weleetka Carter¶, Aaron Owen*, V. Suzanne Klimberg*
Oncology Research, Vol.25, No.8, pp. 1223-1229, 2017, DOI:10.3727/096504017X14876245096439
Abstract Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and
its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient
dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX
cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and
immune trafficking, which was consistent with the increasing number of reports highlighting the important
role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot
study aimed to investigate DNA from patients treated with DOX-based chemotherapy… More >
Login
Register
